DPX-101
Cognitive deficits in Alzheimer’s disease and other CNS disorders
Phase 1Active
Key Facts
Indication
Cognitive deficits in Alzheimer’s disease and other CNS disorders
Phase
Phase 1
Status
Active
Company
About DAMONA Pharmaceuticals
Damona develops α5‑GABA‑A positive allosteric modulators to treat cognitive deficits across neurodegenerative and psychiatric diseases.
View full company profile